Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Turns Off Otsuka’s Abilify Dimmer Switch Graphic

This article was originally published in The Pink Sheet Daily

Executive Summary

As lights go out on the franchise, FDA says pharmacology aid misleadingly suggests Abilify offers advantages over other treatments.

You may also be interested in...

DTC Safety Messages Could Vary By Platform As FDA Considers Screen Size

Both tablets and huge TVs have proliferated since the last research of the impact of superimposed text.

FDA's Rx Promotion Citation Drought Continued In 2015

First Amendment litigation and guidance document work may be factors behind decline.

FDA Cites Akorn’s Exhibit Banner At ASHP Clinical Conference

Booth promotion for Nembutal fails to disclose any risk information, Office of Prescription Drug Promotion says in the fifth letter issued this year.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts